A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans

AIDS

Volumn 28, Issue 9, 2014, Pages 1289-1295

  Scherzer, Rebecca ^a,b   Gandhi, Monica ^a,b   Estrella, Michelle M ^c   Tien, Phyllis C ^a,b   Deeks, Steven G ^a,b   Grunfeld, Carl ^a,b   Peralta, Carmen A ^a,b   Shlipak, Michael G ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic kidney disease; HIV; Risk score; Tenofovir

Indexed keywords

GLUCOSE; TENOFOVIR DISOPROXIL; TRIACYLGLYCEROL; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY DISEASE RISK SCORE; COHORT ANALYSIS; COMORBIDITY; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VETERAN; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; COMPLICATION; HIV INFECTIONS; MIDDLE AGED;

ADENINE; ADULT; ANTI-HIV AGENTS; COHORT STUDIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; VETERANS;

EID: 84922479762     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000258     Document Type: Article

References (30)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. [Updated 12 February 2013]. [Accessed 24 February 2014]
2. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach [Revised]. Geneva: WHO; 2010, http://www.who.int/hiv/pub/arv/adult2010/en/index.html. [Accessed 24 February 2014].
3. Jotwani V, Li Y, Grunfeld C, Choi AI, Shlipak MG. Risk factors for ESRD in HIV-infected individuals: traditional and HIVrelated factors. Am J Kidney Dis 2012; 59:628-635.
4. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109:1004-1009.
5. Choi A, Scherzer R, Bacchetti P, Tien PC, Saag MS, Gibert CL, et al. Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis 2010; 56:872-882.
6. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
7. Squires K, Pozniak AL, Pierone G Jr, Steinhart CR, Berger D, Bellos NC, et al. Tenofovir disoproxil fumarate in nucleosideresistant HIV-1 infection: a randomized trial. Ann Intern Med 2003; 139:313-320.
8. Del Palacio M, Romero S, Casado JL. Proximal tubular renal dysfunction or damage in HIV-infected patients. AIDS Rev 2012; 14:179-187.
9. Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012; 26:867-875.
10. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation 2010; 121:651-658.
11. Backus LI, Gavrilov S, Loomis TP, Halloran JP, Phillips BR, Belperio PS, et al. Clinical case registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc 2009; 16:775-783.
12. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604-612.
13. Choi AI, Rodriguez RA, Bacchetti P, Volberding PA, Havlir D, Bertenthal D, et al. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. Clin Infect Dis 2007; 45:1633-1639.
14. Justice AC, Dombrowski E, Conigliaro J, Fultz SL, Gibson D, Madenwald T, et al. Veterans Aging Cohort Study (VACS): overview and description. Med Care 2006; 44:S13-S24.
15. Office USGA. Veterans healthcare: use of VA services by Medicare- eligible veterans. GAO Report. Washington, DC: United States General Accounting Office; 1994.
16. Shen Y, Hendricks A, Zhang S, Kazis LE. VHA enrollees' healthcare coverage and use of care. Med Care Res Rev 2003; 60:253-267.
17. Wagner JH, Justice AC, Chesney M, Sinclair G, Weissman S, Rodriguez-Barradas M, et al. Patient- and provider-reported adherence: toward a clinically useful approach to measuring antiretroviral adherence. J Clin Epidemiol 2001; 54 (Suppl 1): S91-S98.
18. Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 2011; 25:1289-1298.
19. Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36:1070-1073.
20. Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004; 35:269-273.
21. Hoeting JM, Raftery A, Volinsky C. Bayesian model averaging: a tutorial. Stat Sci 1999; 14:382-401.
22. Sullivan LM, Massaro JM, D'Agostino RB Sr. Presentation of multivariate data for clinical use: the Framingham Study risk score functions. Stat Med 2004; 23:1631-1660.
23. Morlat P, Vivot A, Vandenhende MA, Dauchy FA, Asselineau J, Deti E, et al. Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine Cohort, France, 2004-2012. PLoS One 2013; 8:e66223.
24. Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol 2013; 24:1519-1527.
25. Szczech LA, Gange SJ, van der Horst C, Bartlett JA, Young M, Cohen MH, et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 2002; 61:195-202.
26. Saksena NK, Wang B, Zhou L, Soedjono M, Ho YS, Conceicao V. HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites. HIV AIDS (Auckl) 2010; 2:103-122.
27. Weiner DE, Sarnak MJ. Managing dyslipidemia in chronic kidney disease. J Gen Intern Med 2004; 19:1045-1052.
28. Chmielewski M, Carrero JJ, Nordfors L, Lindholm B, Stenvinkel P. Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach. J Nephrol 2008; 21:635-644.
29. Odden MC, Scherzer R, Bacchetti P, Szczech LA, Sidney S, Grunfeld C, et al. Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study. Arch Intern Med 2007; 167:2213-2219.
30. Lucas GM, Jing Y, Sulkowski M, Abraham AG, Estrella MM, Atta MG, et al. Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis 2013; 208:1240-1249.